Frequently asked questions

Oncocount, Oncotrace or Oncotrail tests can be used to follow up and monitor specific types of tumours.

Our Metastat test provides this information over a period of three years. It compares profiles of CTCs and metastases to detect relevant markers at the site of relapse.

Yes. Patients with lymphoma or leukemia can use an RGCC test to measure their circulating tumour cell count.

Yes. Onconomics and Onconomics Plus tests can be used for Ras–Raf-MEK-Erk, dabrafenib, vemurafenib, c-Jun, C-Fos, trametinib and sorafenib.

You are welcome to send us any substance for testing. We can also include additional natural substances in Onconomics Plus or Onconomics Extracts or additional chemotherapy drugs in the Onconomics test. We also offer combination tests, provided a doctor specifies the ratio of each component in the combination.

RGCC’s circulating tumour cell test has a negative predictive value of about 86%. This means our test will correctly return a true negative result 86% of the time.

If you only need to order the ChemoSNiP test on its own, a swab is suitable. However, if you wish to order other tests in addition to the ChemoSNiP, a patient’s DNA will be isolated from their blood. In this case, a blood sample is sufficient for both tests, so there is no need for a swab.

The ChemoSNiP test provides information about DNA mutations that can affect how humans develop cancer or respond to anti-cancer drugs and treatments.

Yes. The Oncotrace test provides information about the presence of circulating tumour cells, their concentration and immunophenotype, which may help identify their origin. It is used to provide guidance about a patient’s prognosis, and to help identify the primary tumour when this is unknown.

The Immune-Frame test focuses on the status of a patient’s immune system, based on their cellular markers and the level of cytokine proteins in the test sample.

This should be determined by your treatment plan.

Every three months for the first year, then every six months.